Program
Spironolactone
Also written as “Spironolactone Oral Suspension”, “Torsemide and Spironolactone tablet” and “Torsemide Tablets and Spironolactone Tablets”.
Its studies are mostly in Fibrosis · Heart Failure, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CMP Development | 21 open or running | phase 4since Aug 28, 2023 | Feb 16, 2019 | Jun 2028phase 4 · NCT06021860 |
| Sarfez Pharmaceuticals | 20 open or running | phase 3since Jun 3, 2025 | Jun 3, 2025 | none ahead |
| Orion Corporation, Orion Pharma | 10 open or running | phase 1since Mar 8, 2010 | Mar 8, 2010 | none ahead |
| Pfizer | 10 open or running | phase 1since Jan 2, 2024 | Jan 2, 2024 | none ahead |
| SPH Sine Pharmaceutical Laboratories | 10 open or running | phase 1since Aug 26, 2024 | Aug 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2010First study: phase 1 study in HealthyNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT01083290 · 14 enrolled · India
- Feb 16, 2019CMP Development's first study: phase 1 study in Drug Drug InteractionNew to CMP DevelopmentCMP Development · NCT03909529 · 28 enrolled · India
- Aug 28, 2023Phase 4 study in FibrosisCMP Development · NCT06021860 · 96 planned
- Jan 2, 2024Pfizer's first study: phase 1 study in Healthy ParticipantsNew to PfizerPfizer · NCT06205407 · 42 enrolled · United States
- Aug 26, 2024SPH Sine Pharmaceutical Laboratories's first study: phase 1 study in Bioequivalence StudyNew to SPH Sine Pharmaceutical LaboratoriesSPH Sine Pharmaceutical Laboratories · NCT06579053 · 64 enrolled · China
- Jun 3, 2025Sarfez Pharmaceuticals's first studies: 2 phase 3 studiesNew to Sarfez PharmaceuticalsSarfez Pharmaceuticals · NCT07015671, NCT07046975
Ahead
- Jun 2028Primary completion: phase 4 study in FibrosisCMP Development · NCT06021860
TargetBeta
“Mineralocorticoid receptor antagonist”ChEMBL 37, by rule
Other programs on NR3C2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| finerenonerule | Bayer | phase 4 | 25 |
| drospirenonerule | estetra | phase 4 | 20 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| balcinrenonerule | AstraZeneca | phase 3 | 15 |
| HRS-1780 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07046975Bioavailability Heathy Volunteers · United States | 3 | Completed | Sarfez Pharmaceuticals | Feb 28, 2026 | 24 |
| NCT07015671Bioequivalence Study in Healthy Subjects · United States | 3 | Completed | Sarfez Pharmaceuticals | Dec 30, 2025 | 24 |
| NCT06579053Bioequivalence Study · China | 1 | Completed | SPH Sine Pharmaceutical Laboratories | May 5, 2023 | 64 |
| NCT06205407Healthy Participants · United States | 1 | Completed | Pfizer | Mar 1, 2024 | 42 |
| NCT06021860Fibrosis | 4 | Not yet recruiting | CMP Development | Jun 2028 | 96 |
| NCT03909529Drug Drug Interaction · India | 1 | Completed | CMP Development | Apr 19, 2019 | 28 |
| NCT01083290Healthy · India | 1 | Completed | Orion Corporation, Orion Pharma | Apr 2010 | 14 |
How it is read
Names in the registry
- “Spironolactone”, 4 entries
- “Spironolactone Oral Suspension”, 1 entry
- “Torsemide and Spironolactone tablet”, 1 entry
- “Torsemide Tablets and Spironolactone Tablets”, 1 entry
- “25 mg Aldactone (Spironolactone) tablet”, 1 entry
Conditions, from the studies’ own filings
- Fibrosis, 1 study
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.